IL37 and psoriasis: In an effort to further understand the immune tolerance mechanism behind the short-term IL-23 blockade associated with long-term disease remission, moderate-to-severe psoriasis clinical trials with scRNA-seq analyses of human skin are currently taking place in the US (NCT04630652).